IBDEI1M9 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,757,0)
 ;;=PREVENTIVE MED-EST PT^4^60
 ;;^UTILITY(U,$J,358.4,758,0)
 ;;=PREVENTIVE MED-NEW PT^5^60
 ;;^UTILITY(U,$J,358.4,759,0)
 ;;=TRANSITIONAL CARE MGMT (TCM)^6^60
 ;;^UTILITY(U,$J,358.4,760,0)
 ;;=PC COMMON DIAGNOSES^1^61
 ;;^UTILITY(U,$J,358.4,761,0)
 ;;=ADMINISTRATIVE TOPICS^15^61
 ;;^UTILITY(U,$J,358.4,762,0)
 ;;=ANGINA^16^61
 ;;^UTILITY(U,$J,358.4,763,0)
 ;;=ATHEROSCLEROSIS^17^61
 ;;^UTILITY(U,$J,358.4,764,0)
 ;;=CARDIOVASCULAR^18^61
 ;;^UTILITY(U,$J,358.4,765,0)
 ;;=DERMATOLOGY^22^61
 ;;^UTILITY(U,$J,358.4,766,0)
 ;;=EAR DISORDERS^24^61
 ;;^UTILITY(U,$J,358.4,767,0)
 ;;=EENT^25^61
 ;;^UTILITY(U,$J,358.4,768,0)
 ;;=ENDOCRINE/METABOLIC^26^61
 ;;^UTILITY(U,$J,358.4,769,0)
 ;;=EYE DISORDERS^27^61
 ;;^UTILITY(U,$J,358.4,770,0)
 ;;=EYE INJURY^28^61
 ;;^UTILITY(U,$J,358.4,771,0)
 ;;=GASTROENTEROLOGY^29^61
 ;;^UTILITY(U,$J,358.4,772,0)
 ;;=GU/RENAL^30^61
 ;;^UTILITY(U,$J,358.4,773,0)
 ;;=HEADACHE^31^61
 ;;^UTILITY(U,$J,358.4,774,0)
 ;;=HEART VALVE DISEASE^32^61
 ;;^UTILITY(U,$J,358.4,775,0)
 ;;=HEMATOLOGY/ONCOLOGY^33^61
 ;;^UTILITY(U,$J,358.4,776,0)
 ;;=HISTORY OF ILLNESS^34^61
 ;;^UTILITY(U,$J,358.4,777,0)
 ;;=INFECTIOUS DISEASE^35^61
 ;;^UTILITY(U,$J,358.4,778,0)
 ;;=LIVER DISEASE^36^61
 ;;^UTILITY(U,$J,358.4,779,0)
 ;;=MENTAL HEALTH^38^61
 ;;^UTILITY(U,$J,358.4,780,0)
 ;;=MOVEMENT DISORDERS^39^61
 ;;^UTILITY(U,$J,358.4,781,0)
 ;;=MUSCULOSKELETAL^40^61
 ;;^UTILITY(U,$J,358.4,782,0)
 ;;=NEUROLOGY^41^61
 ;;^UTILITY(U,$J,358.4,783,0)
 ;;=PAIN^42^61
 ;;^UTILITY(U,$J,358.4,784,0)
 ;;=PREVENTIVE HEALTH^43^61
 ;;^UTILITY(U,$J,358.4,785,0)
 ;;=PULMONARY^44^61
 ;;^UTILITY(U,$J,358.4,786,0)
 ;;=SEXUAL TRAUMA^45^61
 ;;^UTILITY(U,$J,358.4,787,0)
 ;;=SIGNS,SYMPTOMS,CONDITIONS^46^61
 ;;^UTILITY(U,$J,358.4,788,0)
 ;;=SPRAIN/STRAIN-INITIAL ENCOUNTER^47^61
 ;;^UTILITY(U,$J,358.4,789,0)
 ;;=SUBSTANCE DISORDERS^48^61
 ;;^UTILITY(U,$J,358.4,790,0)
 ;;=VARICOSE VEINS^50^61
 ;;^UTILITY(U,$J,358.4,791,0)
 ;;=WOMEN'S HEALTH^51^61
 ;;^UTILITY(U,$J,358.4,792,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^52^61
 ;;^UTILITY(U,$J,358.4,793,0)
 ;;=COMA^20^61
 ;;^UTILITY(U,$J,358.4,794,0)
 ;;=CAUSES OF INJURY^19^61
 ;;^UTILITY(U,$J,358.4,795,0)
 ;;=DEMENTIA^21^61
 ;;^UTILITY(U,$J,358.4,796,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^37^61
 ;;^UTILITY(U,$J,358.4,797,0)
 ;;=ACQUIRED ABSENCE OF BODY PART(S)^2^61
 ;;^UTILITY(U,$J,358.4,798,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^49^61
 ;;^UTILITY(U,$J,358.4,799,0)
 ;;=ACSC ACUTE KIDNEY FAILURE^3^61
 ;;^UTILITY(U,$J,358.4,800,0)
 ;;=ACSC ANGINA^4^61
 ;;^UTILITY(U,$J,358.4,801,0)
 ;;=ACSC ASTHMA/BRONCHITIS/COPD^5^61
 ;;^UTILITY(U,$J,358.4,802,0)
 ;;=ACSC CHF^6^61
 ;;^UTILITY(U,$J,358.4,803,0)
 ;;=ACSC DEHYDRATION^7^61
 ;;^UTILITY(U,$J,358.4,804,0)
 ;;=ACSC DIABETES TYPE 1^8^61
 ;;^UTILITY(U,$J,358.4,805,0)
 ;;=ACSC DIABETES TYPE 2^9^61
 ;;^UTILITY(U,$J,358.4,806,0)
 ;;=ACSC HYPERTENSION^10^61
 ;;^UTILITY(U,$J,358.4,807,0)
 ;;=ACSC INFECTIOUS GASTROENTERITIS^11^61
 ;;^UTILITY(U,$J,358.4,808,0)
 ;;=ACSC PNEUMONIA^12^61
 ;;^UTILITY(U,$J,358.4,809,0)
 ;;=ACSC UTI^13^61
 ;;^UTILITY(U,$J,358.4,810,0)
 ;;=ACSC VIRAL ENTERITIS^14^61
 ;;^UTILITY(U,$J,358.4,811,0)
 ;;=E-CIG/VAPE LUNG INJURY^23^61
 ;;^UTILITY(U,$J,358.4,812,0)
 ;;=BLOODS, ARTERIAL & VENOUS^1^62
 ;;^UTILITY(U,$J,358.4,813,0)
 ;;=OXIMETRY (WHEN ONLY SERVICE)^7^62
 ;;^UTILITY(U,$J,358.4,814,0)
 ;;=PULMONARY FUNCTION TESTING^9^62
 ;;^UTILITY(U,$J,358.4,815,0)
 ;;=THORACENTESIS^11^62
